TRUNOME: Diagnosis And Monitoring Platform For Chronic Diseases
SEASON 2TECHNOLOGY
Trunome: Revolutionizing Chronic Disease Diagnosis and Monitoring
Trunome is a cutting-edge technology platform that is transforming the way chronic diseases are diagnosed and monitored. With a focus on post-transplant patients, Trunome offers safe, accurate, and early detection of graft rejection and injury. By leveraging innovative technology, Trunome is disrupting the traditional approach to chronic disease management and providing patients with better outcomes.
A Shark Tank India Success Story
Trunome's groundbreaking technology caught the attention of the judges on Shark Tank India Season 2. Their pitch impressed the sharks, and they secured an investment of ₹ 1.5 crores for 2% Equity from Anupam Mittal, Vineeta Singh, Aman Gupta, and Peyush Bansal. While the original offer was for ₹ 1.5 crores for 1% Equity, the sharks recognized the immense potential of Trunome and negotiated for a higher stake.
Why Choose Trunome?
Trunome offers a multitude of benefits for post-transplant patients and healthcare providers:
Early Detection: Trunome's technology enables early detection of graft rejection and injury, allowing for timely intervention and improved patient outcomes.
Accurate Diagnosis: Trunome's diagnostic tests are highly accurate, providing reliable information for treatment decisions.
Non-Invasive: Unlike traditional diagnostic methods, Trunome's approach is non-invasive, reducing discomfort and risk for patients.
Remote Monitoring: Trunome's platform enables remote monitoring of patients, allowing for better management and reduced healthcare costs.
Experience the Future of Chronic Disease Care
Trunome is revolutionizing the way chronic diseases are managed. By providing early detection, accurate diagnosis, and non-invasive monitoring, Trunome is empowering patients and healthcare providers to achieve better outcomes.
Click here to learn more about Trunome and how it can benefit you or your patients!